Articles from Ray Therapeutics

Ray Therapeutics, a clinical-stage biotechnology company developing optogenetic gene therapies for vision restoration, today announced the appointment of Michael Murtagh as Chief Regulatory Officer. With more than 20 years of experience in regulatory affairs, Michael has led multiple Investigational New Drug Applications (INDs), Clinical Trial Applications (CTAs) and marketing applications across a range of indications, spanning therapeutic areas including oncology, cardiovascular disease, neurology and inborn errors of metabolism.

Ray Therapeutics, a clinical-stage biotechnology company developing optogenetic gene therapies for vision restoration, today announced the appointment of Scott Braunstein, M.D., as Chairman of the company’s Board of Directors. The company’s lead program, RTx-015, is currently being evaluated in a Phase 1 clinical trial to treat retinitis pigmentosa (RP). Ray Therapeutics is also poised to dose the first patient in a Phase 1 clinical trial of RTx-021 for Stargardt disease.

Ray Therapeutics, a biotechnology company developing optogenetic gene therapies for vision restoration, today announced it has been awarded an $8 million grant from the California Institute for Regenerative Medicine (CIRM). The grant will support the company’s ongoing clinical development of RTx-015 for the treatment of retinitis pigmentosa (RP), a progressive and debilitating inherited retinal disease that leads to blindness.

Ray Therapeutics, a leading optogenetics company, announced today the appointment of Christopher Whitmore as Chief Financial Officer.

Ray Therapeutics, a leading optogenetics company, announced today that the California Institute for Regenerative Medicine (CIRM) has awarded the company a $4M grant to support development of RTx-021, an optogenetic therapy for the treatment of geographic atrophy (GA), the advanced form of age-related macular degeneration (AMD).

Ray Therapeutics, a leading optogenetics medicines company, today announced the promotion of Jenny Holt to Chief Development Officer.

Ray Therapeutics, a leading optogenetics company, today announced an upsized and oversubscribed $100M Series A financing round led by Novo Holdings A/S, and joined by Deerfield Management, Norwest Venture Partners, Platanus, MRL Ventures Fund, the therapeutics-focused corporate venture fund of Merck & Co., Inc., and existing investor 4BIO Capital. The funding will advance multiple programs targeting blinding diseases of the eye through clinical development.

Ray Therapeutics, a biotech company developing optogenetic gene therapies for patients with blinding diseases, announced today that Peter Francis, M.D., Ph.D., Chief Scientific and Medical Officer, will present at two upcoming scientific conferences: the 2023 Cell & Gene Meeting on the Med and the Eighth Annual Retinal Cell and Gene Therapy Innovation Summit (held during the 2023 ARVO Annual Meeting).

Ray Therapeutics, a biotech company whose mission is to restore vision to patients with blinding eye diseases, today announced the appointment of Peter Francis, M.D., Ph.D., as Chief Scientific & Medical Officer, and Jenny Holt as Senior Vice President, Program Portfolio Management.

Ray Therapeutics, a biotechnology company developing optogenetic gene therapies for patients with retinal degenerative conditions, announced today that the California Institute for Regenerative Medicine (CIRM) has awarded the company a $4M grant to support development of Ray-001, an optogenetic therapy for the treatment of retinitis pigmentosa and other inherited retinal diseases.

Ray Therapeutics, a biotech company developing optogenetic gene therapies for patients with blinding diseases, today announced the closing of a $6M seed financing round, led by 4BIO Capital.